This announcement isn’t about Neuron, it’s about the FDA.In...

This announcement isn’t about Neuron, it’s about the FDA.

In 2025, around 3,500 employees were cut as part of a large staffing reduction at the Department of Health and Human Services (HHS), which oversees the FDA.

This has increased FDA workload, slows everything down, and makes face-to-face meetings harder to get.

When experienced reviewers leave or are laid off:

• Fewer reviewers are covering the same number of programs
• Institutional knowledge is lost
• Files get reassigned, often multiple times
• Response times stretch — even if official “goal dates” stay the same on paper.
• Each reviewer handles more INDs, more meetings, more documents — with less time.
• That pushes the FDA toward lower-effort interaction formats.

Why face-to-face FDA meetings drop first.

• Live meetings (Type B / Type C) are time-intensive:
• Prep by multiple FDA disciplines
• Internal alignment meetings
• Real-time discussion + follow-up minutes
• Senior reviewer involvement.

BUYING OPPORTUNITY